Moderna Just Made the Pfizer Vaccine's Biggest Weakness an Even Bigger One

Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) have been close rivals in the COVID-19 vaccine race ever since they announced the starts of their phase 3 vaccine trials -- on the very same day back in July. But Pfizer edged ahead en route to the finish line. The big pharmaceutical company scored the first FDA emergency use authorization (EUA) for a coronavirus vaccine in December.